TMEM173 is a biomarker of predicting prognosis, immune responses and therapeutic effect in human Lung Adenocarcinoma
Preprint in Research Square (November 2023)
The most recent citing publications are shown below. View all 16 publications that cite this research output on Dimensions.
Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB
Article in Scientific Reports (December 2022)
Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies
Article in Biomedicine & Pharmacotherapy (April 2022)